Xanodyne's low-dose NSAID Zipsor approved in the US
This article was originally published in Scrip
Xanodyne Pharmaceuticals has received US approval for its low-dose NSAID Zipsor (diclofenac potassium) 25mg liquid filled capsules, for the relief of mild to moderate acute pain in adults.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.